Thoracic Cancer最新文献

{"title":"Endobronchial Metastasis From Osteosarcoma in an Adolescent: A Rare Case Report.","authors":"Yanling He, Yanping Chen, Yanhong Liu, Juyan Chen, Ahmad Muhammad, Huiwen Jin, Yi Xiao","doi":"10.1111/1759-7714.70355","DOIUrl":"10.1111/1759-7714.70355","url":null,"abstract":"<p><p>A 14-year-old female was diagnosed with osteosarcoma of the left proximal tibia and underwent neoadjuvant chemotherapy followed by wide local resection and limb-sparing surgery. Thirteen months after surgery, she developed coughing, wheezing, and shortness of breath. Chest CT revealed stenosis in the right main and middle bronchi with a soft-tissue density lesion. No suspicious metastatic lesions were observed around the airways, and the analysis of bronchoscopic biopsy specimens confirmed a rare endobronchial metastasis of osteosarcoma. Despite bronchoscopic intervention, the patient eventually died due to late detection and rapid tumor progression. These findings suggest that early bronchoscopic assessment of the airway mucosa is critical.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 14","pages":"e70355"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148473051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Functional Impact of Resecting Additional Ipsilateral Ground-Glass Opacities: A Retrospective Propensity Score-Matched Study.","authors":"Jia Han, Guofei Zhang, Yaojuan Jin, Junqiang Fan","doi":"10.1111/1759-7714.70344","DOIUrl":"10.1111/1759-7714.70344","url":null,"abstract":"<p><strong>Background: </strong>The 1-year pulmonary functional impact of resecting additional ipsilateral ground-glass opacities (GGOs) during unilateral surgery remains uncertain. We evaluated whether resection of multiple ipsilateral GGOs is associated with less favorable postoperative pulmonary function preservation than resection of a single lesion.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with at least two ipsilateral GGOs who underwent pulmonary surgery between January 2020 and December 2024. Patients were grouped according to whether 1 lesion or ≥ 2 lesions were resected during the index operation. The primary outcomes were 1-year retention of FVC, FEV1, and DLCOc-SB.</p><p><strong>Results: </strong>A total of 291 patients were included; 146 underwent resection of 1 lesion and 145 underwent resection of ≥ 2 lesions. After propensity score matching, 232 patients remained (116 per group). In the matched cohort, absolute postoperative FVC, FEV1, and DLCOc-SB at 1 year were similar between groups. However, resection of ≥ 2 lesions was associated with greater declines and lower retention of FVC (90.41% vs. 94.55%; p < 0.001), FEV1 (87.10% vs. 93.73%; p < 0.001), and DLCOc-SB (91.04% vs. 93.70%; p = 0.016). In multivariable analyses, resection of ≥ 2 lesions remained independently associated with lower FEV1, FVC, and DLCOc-SB retention. Operative time was longer in the ≥ 2-lesion group, whereas other perioperative outcomes were similar.</p><p><strong>Conclusions: </strong>Among surgically fit patients with multiple ipsilateral GGOs, resection of ≥ 2 lesions was associated with less favorable pulmonary function preservation than resection of a single lesion, suggesting a functional trade-off when considering resection of additional ipsilateral lesions.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 13","pages":"e70344"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13329688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148377163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-1α-Mediated Activation of TNF-α/NF-κB Signaling Confers Resistance to Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer.","authors":"Wira Winardi, Yoichiro Mitsuishi, Hironari Matsuda, Fumiyuki Takahashi, Daisuke Hayakawa, Koichiro Kanamori, Ikuko Nakamura, Aditya Wirawan, Moulid Hidayat, Adityo Wibowo, Takehito Shukuya, Ken Tajima, Takuo Hayashi, Shinji Kohsaka, Kazuhisa Takahashi","doi":"10.1111/1759-7714.70360","DOIUrl":"10.1111/1759-7714.70360","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is the leading cause of cancer-related deaths worldwide. Although osimertinib is more effective than previous-generation drugs, its efficacy is often limited by both primary and acquired resistance. Cycling cancer persister cells (CPCs) have recently emerged as a transient, drug-tolerant subpopulation that may contribute to early resistance to targeted therapies. However, their biological characteristics and role in osimertinib resistance remain poorly understood.</p><p><strong>Methods: </strong>We established osimertinib-resistant CPCs derived from epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) cell lines PC9 and HCC827. RNA sequencing (RNA-seq) was performed to identify CPC-specific transcriptional programs.</p><p><strong>Results: </strong>RNA-seq analyses demonstrated that the tumor necrosis factor alpha (TNF-α)/nuclear factor-κB (NF-κB) signaling pathway was upregulated in osimertinib-resistant PC9 cells (PC9-CPCs), with interleukin-1 alpha (IL-1α) being the most significantly overexpressed gene. Treatment with IL-1α increased TNF-α and NF-κB p65 expression in PC9 parental cells, whereas IL-1α inhibition decreased TNF-α expression in PC9-CPCs. Consequently, the inhibition of either IL-1α or TNF-α restored the sensitivity of EGFR-mutant NSCLC cells to osimertinib. Immunohistochemical analysis confirmed that NF-κB expression was higher in tumor specimens from patients who had developed osimertinib resistance than in specimens collected before treatment.</p><p><strong>Conclusion: </strong>CPCs exhibit a distinct inflammatory phenotype driven by IL-1α-driven activation of the TNF-α/NF-κB axis, representing an alternative mechanism underlying osimertinib resistance. Targeting IL-1α or TNF-α may provide a promising strategy to overcome resistance in patients with EGFR-mutant NSCLC.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 14","pages":"e70360"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148473037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transformation or Clonal Evolution? A Rare Case Report of Pulmonary Sarcomatoid Carcinoma Developing to Small Cell Lung Cancer.","authors":"Wen Jiang, Yuwei Zhang, Xingmei Li, Qi Si, Zhaohuan Ye, Youfeng Ma, Haitao Zhou, Jianwei Huang, Chao Zhang, Ge Zhang","doi":"10.1111/1759-7714.70341","DOIUrl":"10.1111/1759-7714.70341","url":null,"abstract":"<p><p>Many cases of non-small cell lung cancer (NSCLC) transforming to small cell lung cancer (SCLC) after targeted therapy have been reported, most of which are associated with acquired resistance mutations. Herein, we report the first documented case of phenotypic conversion to SCLC in a patient with advanced pulmonary sarcomatoid carcinoma (PSC) who received pemetrexed, carboplatin, and camrelizumab only, with no targeted agents administered. Through comparative analysis of two serial pathological biopsies and genetic profiling, our findings suggest that PSC may undergo clonal evolution or alternative transformation mechanisms under therapeutic pressure. TP53 and RET mutations may be implicated in this phenotypic transition. This case provides new insights into the biological mechanism underlying the evolution of PSC to SCLC.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 13","pages":"e70341"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13318924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Collision Tumor Comprising Lung Adenocarcinoma and Metastatic Endometrial Cancer: A Case Report.","authors":"Momoko Asami, Hayato Konno, Shinya Katsumata, Hideaki Kojima, Naoya Yokomakura, Mitsuhiro Isaka, Nobuhiro Kado, Takuya Kawata, Masahiro Endo, Yasuhisa Ohde","doi":"10.1111/1759-7714.70339","DOIUrl":"10.1111/1759-7714.70339","url":null,"abstract":"<p><p>We report a rare case of a 78-year-old woman with a collision tumor composed of primary lung adenocarcinoma and metastatic endometrial cancer. The patient previously underwent hysterectomy and adjuvant chemotherapy for Stage IIIC1 endometrial cancer. Chest computed tomography (CT) revealed a ground-glass nodule in the right upper lobe, which was suspected to be inflammatory scarring. Two years later, new adjacent nodules emerged, both of which gradually increased in size and exhibited partial collisions. A lobectomy was performed to detect multiple synchronous lung cancers. Histological features of the surgical specimens included acinar adenocarcinoma and metastatic lung tumors of endometrial cancer. To the best of our knowledge, this is the first report of a pulmonary collision tumor consisting of a lung adenocarcinoma and a metastatic lung tumor of endometrial cancer, with serial CT imaging successfully capturing the collision between the two lesions.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 13","pages":"e70339"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148382837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Manifestations and Outcomes of Lung Cancer Patients With Appendiceal Metastasis.","authors":"Kangjian Cui, Huayuan Chen, Xiaojing Cao, Hongbo Wang, Zhigang Wang","doi":"10.1111/1759-7714.70318","DOIUrl":"10.1111/1759-7714.70318","url":null,"abstract":"<p><p>Metastatic involvement of the appendix from a primary distant tumor is uncommon, and the same holds true for tumors originating in the lungs. Consequently, data on pathogenesis, diagnostic approaches, therapeutic strategies, and outcomes of lung-to-appendix metastasis remain scarce. Here we describe two patients managed at our institution between September 2018 and August 2025 and integrate their data with 30 cases identified through a structured literature search, yielding an analytical cohort of 32 individuals. The cohort comprised 26 males and 6 females, with a median age at detection of appendiceal involvement of 63.5 years (range, 41-85 years). The median interval from primary lung-cancer diagnosis was 12 months (range, 1-54 months). Histotypes were small-cell carcinoma (n = 15), adenocarcinoma (n = 14), squamous-cell carcinoma (n = 1) and not otherwise specified (n = 2). At the time of appendiceal disease, 20 patients (62.5%) already harbored concurrent extra-appendiceal metastases. Surgical intervention was undertaken in 31 cases; appendectomy-performed open or laparoscopically-was the procedure of choice in 26 (83.9%). In summary, the appendix may serve as an unusual but clinically relevant sanctuary site in patients with advanced lung cancer, particularly those with small-cell or adenocarcinomatous histology. Systematic staging, tailored surgical resection, and individualized systemic therapy are essential to prolong survival and preserve quality of life.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 13","pages":"e70318"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Vigilance Beyond Hypertension With Lenvatinib in Thymic Carcinoma.","authors":"Ashish Gupta, Amulya Gade, Ashish Subedi","doi":"10.1111/1759-7714.70352","DOIUrl":"10.1111/1759-7714.70352","url":null,"abstract":"","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 13","pages":"e70352"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13365350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study.","authors":"Anand Shah, Pranav Gwalani, Merry Zhai, Ritik Goyal, Joshua Kra","doi":"10.1111/1759-7714.70359","DOIUrl":"10.1111/1759-7714.70359","url":null,"abstract":"<p><strong>Background: </strong>The optimal sequencing of brain-directed radiation and systemic therapy in stage IV non-small cell lung cancer (NSCLC) with brain metastases remains uncertain in the era of CNS-active systemic agents. We evaluated survival outcomes using national real-world data.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of adults diagnosed between 2010 and 2022 with stage IV NSCLC and brain metastases in the National Cancer Database who received both brain-directed radiation and systemic therapy. Treatment sequence was classified as radiation-first or systemic-first based on initiation dates. Multivariable Cox proportional hazards models, stratified by treatment era (pre-2015 vs. 2015+), assessed associations with overall survival (OS), adjusting for demographic, clinical, tumor, and treatment factors. Propensity score matching and delayed-entry sensitivity analyses were performed to address confounding and immortal time bias.</p><p><strong>Results: </strong>Among 45 577 patients, 78.3% received radiation-first and 21.7% received systemic therapy first. Unadjusted Kaplan-Meier analysis showed no significant difference in OS (log-rank p = 0.624). In multivariable analysis, systemic-first sequencing was associated with a modest increase in mortality (adjusted hazard ratio [aHR] 1.06; 95% CI: 1.04-1.09), which was consistent in propensity-matched (HR 1.07; 95% CI: 1.04-1.11) and delayed-entry analyses (aHR 1.09; 95% CI: 1.07-1.12). The use of systemic-first therapy increased over time. Established prognostic factors demonstrated larger effect sizes.</p><p><strong>Conclusion: </strong>Systemic-first sequencing was associated with a modest increase in adjusted mortality; however, the effect size was small relative to established prognostic factors and likely influenced by residual confounding and selection bias. These findings support individualized, multidisciplinary treatment decisions rather than a uniform sequencing strategy.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 14","pages":"e70359"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13381076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review and Meta-Analysis.","authors":"Soo Han Kim, Hayoung Seong, Hyojin Jang, Saerom Kim, Wanho Yoo, Jeongha Mok, Kwangha Lee, Ki Uk Kim, Min Ki Lee, Mi-Hyun Kim, Jung Seop Eom","doi":"10.1111/1759-7714.70312","DOIUrl":"10.1111/1759-7714.70312","url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of EGFR mutations in resected non-small cell lung cancer (NSCLC) remains uncertain despite their established predictive value in advanced disease. We assessed the prognostic impact of EGFR mutation status on recurrence and disease-free survival (DFS) in resected stage I-III NSCLC.</p><p><strong>Methods: </strong>In this systematic review and meta-analysis, we searched PubMed, Embase, and Cochrane Library to identify studies of resected stage I-III NSCLC reporting recurrence or DFS according to EGFR status. Pooled recurrence rates, risk ratio (RR), and hazard ratio (HR) were calculated using random-effects models. Subgroup analyses were conducted by stage, recurrence site, mutation subtype, and adjuvant treatment.</p><p><strong>Results: </strong>A total of 20 studies (4 randomized controlled trials and 16 retrospective observational studies), comprising 12 123 patients (7203 EGFR-mutant and 4920 wild-type), were included. Four studies focused on stage I disease, five on stage II-III, and eleven across stage I-III. The pooled recurrence RR comparing EGFR-mutant and wild-type tumors was 1.04 (95% CI, 0.88-1.23), and the pooled DFS HR was 1.07 (95% CI, 0.84-1.37), indicating no significant difference. Recurrence patterns were comparable, with no differences in local or distant relapse and only a modest, non-significant increase in central nervous system recurrence. Among EGFR-mutant tumors, adjuvant EGFR-TKIs improved DFS (HR 0.45, 95% CI, 0.29-0.71) unlike chemotherapy (HR 1.05, 95% CI, 0.67-1.66).</p><p><strong>Conclusion: </strong>EGFR mutation status is not associated with recurrence, DFS, or recurrence patterns in resected NSCLC. Adjuvant EGFR-TKIs, but not chemotherapy, confer significant DFS benefit, supporting their use as standard postoperative therapy.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 13","pages":"e70312"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13341228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence Patterns and Prognostic Impact of Lung-Involving Multiple Primary Cancers: A 10-Year Hospital-Based Cohort Study.","authors":"Hayoung Kim, Jin-Hee Kwon, Heyjin Kim, Jin Kyung Lee, Young Jun Hong, Hye-Ryoun Kim","doi":"10.1111/1759-7714.70340","DOIUrl":"10.1111/1759-7714.70340","url":null,"abstract":"<p><strong>Background: </strong>Multiple primary cancers (MPCs) are increasingly recognized among lung cancer survivors; however, incidence patterns and prognostic impact of lung-involving MPCs (MPC-LC) remain incompletely characterized, particularly given substantial competing mortality. This study aimed to quantify MPC-LC burden and patterns, identify predictors of incident MPC following lung cancer diagnosis, and evaluate factors associated with overall survival.</p><p><strong>Methods: </strong>Patients diagnosed with lung cancer between 2013 and 2022 at Korea Cancer Center Hospital were retrospectively analyzed. MPCs were ascertained using Surveillance, Epidemiology, and End Results multiple-primary rules and classified by synchronicity and sequence. Incident metachronous MPCs (mMPC) following lung cancer diagnosis were evaluated using landmark Fine-Gray models, with death as a competing event. OS was assessed using multivariate time-varying Cox models with landmark and lag-time sensitivity analyses.</p><p><strong>Results: </strong>MPC-LC was detected in 317 of 3195 patients (9.9%; 99 synchronous, 218 metachronous). The 3- and 5-year cumulative incidence of mMPC was 7.3% and 9.6%, respectively, whereas competing mortality was 56.2% and 77.0%. Although unadjusted Kaplan-Meier estimates suggested longer crude survival in patients with MPC-LC, time-aware analyses demonstrated an association between MPC-LC and increased mortality, persisting across inverse probability of treatment weighting and sensitivity analyses. Advanced or unknown stage and neuroendocrine carcinoma histology were adverse prognostic factors.</p><p><strong>Conclusions: </strong>MPC-LC occurs amid substantial competing mortality, and its prognostic impact is best understood using bias- and time-aware analytical approaches. These findings support stage- and histology-informed surveillance and coordinated multidisciplinary care in thoracic oncology.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 13","pages":"e70340"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13328836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148377199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}